Senti Bio appoints K5 Global co-founder Bryan Baum to board of directors

SOUTH SAN FRANCISCO - Senti Biosciences, Inc. (NASDAQ:SNTI) announced Friday the appointment of Bryan Baum to its Board of Directors. Baum is the Co-Founder and Managing Partner of K5 Global, a venture capital firm with investments in companies including SpaceX, OpenAI, and Databricks. The appointment comes as the clinical-stage biotech company, currently valued at $52.4 million, faces significant challenges with cash burn and profitability, according to InvestingPro analysis.

Baum brings entrepreneurial experience to the clinical-stage biotechnology company, having founded and sold multiple ventures including Parrot, a legal tech company using AI that was acquired by Filevine earlier this year, and Blue Vision Labs, sold to Lyft in 2018.

"We are pleased to welcome Bryan to our Board of Directors," said Timothy Lu, Senti Bio’s Co-Founder and Chief Executive Officer, according to the company’s press release.

Baum has made over 200 personal investments in companies such as Uber, Airbnb, and Slack. He was named a Technology Pioneer by the World Economic Forum and featured in Forbes 30 under 30.

Senti Bio is developing cell and gene therapies using its proprietary Gene Circuit platform, which is designed to precisely target cancer cells while sparing healthy cells. The company’s pipeline includes cell therapies engineered with Gene Circuits targeting various liquid and solid tumor indications.

The company’s technology has shown preclinical efficacy in both natural killer (NK) and T cells, according to the statement. Senti Bio is also exploring applications beyond oncology through partnerships.

Baum studied Game Theory at Swarthmore College and Oxford University and previously served as an adjunct professor at the University of Southern California.

In other recent news, Senti Biosciences has reported promising preliminary results from its Phase 1 clinical trial of SENTI-202, a treatment for relapsed or refractory hematologic malignancies, including acute myeloid leukemia (AML). The trial, which was presented at the American Association for Cancer Research Annual Meeting 2025, showed no dose-limiting toxicities and identified a recommended Phase 2 dose. Out of seven evaluable patients, five achieved an overall response rate, with three complete remissions. The U.S. Food and Drug Administration granted Orphan Drug Designation to SENTI-202, offering benefits such as tax credits and potential market exclusivity. Laidlaw analysts initiated coverage on Senti Biosciences with a Buy rating, highlighting the novel approach of SENTI-202. The company also shared preliminary financial results, reporting cash and cash equivalents of approximately $33.8 million for the first quarter of 2025. Research and development expenses increased slightly to $9.3 million, while general and administrative expenses decreased to $7.1 million. The net loss for the quarter was $14.1 million.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.